Strategic Acquisition: KKR Backs Precision Component Leader Precipart for Accelerated Market Expansion

Precipart, a globally recognized manufacturer of highly engineered precision components, has attracted investment from KKR, a major alternative asset management firm. The investment will fuel the company’s continued expansion through both organic growth initiatives and strategic acquisitions in the medical device and aerospace sectors.

Investment Scope and Strategic Framework

KKR is channeling capital into Precipart via its Health Care Strategic Growth Fund II, which carries a $4.0 billion corpus dedicated to high-potential health care enterprises. This funding mechanism reflects KKR’s substantial commitment to the health care ecosystem—the firm has directed more than $20 billion toward the sector since 2004.

The specific financial parameters of this transaction remain undisclosed. However, the arrangement preserves the Laubscher family’s influential position, as they maintain substantial minority ownership while welcoming KKR as a collaborative partner.

About Precipart: Seven Decades of Engineering Excellence

Established in 1950, Precipart emerged from Swiss engineering traditions and has evolved into a comprehensive solution provider for precision components and assemblies. The company specializes in serving original equipment manufacturers (OEMs) across multiple verticals, with particular strength in medical devices, aerospace, and industrial applications.

The manufacturing portfolio spans precision machining, micro-mechanical components, gear systems, motion control solutions, technical ceramics, and additive manufacturing capabilities. Notably, Precipart has gained prominence as a global specialist in gears and motion control technologies, with particular recognition in surgical robotics applications.

Market Positioning and Growth Drivers

The medical device sector faces mounting complexity in supply chain management and the need for sophisticated, scalable manufacturing partners. Oliver Laubscher, serving as CEO of Precipart, highlighted that the KKR partnership enables the company to “expand capability offerings substantially, serve customers at greater scale, and enhance our organizational appeal to top talent.” The leadership team has stewarded the enterprise through 73 years of market development.

Ali Satvat, a KKR partner overseeing Health Care Strategic Growth initiatives globally, characterized Precipart as possessing “foundational strength and customer orientation” necessary to achieve platform-scale status. Anuv Ratan, also representing KKR, emphasized the firm’s confidence in Precipart’s positioning as an emerging best-in-class solution provider capable of managing supply chain intricacy for medical device OEMs.

Strategic Implications and Future Direction

This investment exemplifies KKR’s Health Care Strategic Growth methodology: identifying established leaders within thematic sectors where the firm possesses deep historical insight and can facilitate strategic scaling. The partnership enables Precipart to pursue both organic expansion and inorganic consolidation opportunities.

Completion remains contingent on standard transactional conditions. The arrangement represents a recognition of Precipart’s market standing and positions the company for enhanced geographic reach, expanded service capabilities, and accelerated innovation in precision engineering solutions.